GlassScriptPhysician profile
Gary N Dunetz
NPI 1265528640
$666.06
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.09 · 2020: $65.03 · 2021: $80.65 · 2022: $314 · 2023: $80.38 · 2024: $87.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $167.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $126.40 | 2022-2023 | Botox |
| Boston Scientific Corporation | $85.84 | 2019-2022 | |
| Teleflex LLC | $56.32 | 2022-2024 | Urolift |
| Endo Pharmaceuticals INC. | $52.86 | 2022 | |
| Allergan, INC. | $44.13 | 2021-2022 | |
| Astellas Pharma US INC | $40.47 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $31.65 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.97 | 2022 | |
| Progenics Pharmaceuticals, INC. | $26.13 | 2024 | |
| Sumitomo Pharma America, INC. | $25.75 | 2023 | Gemtesa |
| Coloplast Corp | $25.63 | 2020 | |
| Cook Medical LLC | $24.42 | 2024 | Roadrunner |
| Myovant Sciences INC. | $23.90 | 2022 | |
| Urogen Pharma, INC. | $21.98 | 2022 | |
| Ferring Pharmaceuticals INC. | $21.14 | 2024 | Adstiladrin |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $16.94 | 2022 | |
| Blue Earth Diagnostics | $15.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Dunetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.